Open AccessTherapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug
Author(s) -
Esther Meijer,
R. T. Gansevoort,
Paul E. de Jong,
A M van der Wal,
Wouter N. Leonhard,
S. R. de Krey,
Jacob van den Born,
Gemma M. Mulder,
Harry van Goor,
Joachim Struck,
Emile de Heer,
Dorien J.M. Peters
Publication year - 2011
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfr069
Subject(s) - medicine , polyuria , polydipsia , autosomal dominant polycystic kidney disease , vasopressin , vasopressin receptor , arginine vasopressin receptor 2 , polycystic kidney disease , dosing , antagonist , kidney disease , endocrinology , disease , pharmacology , drug , receptor antagonist , receptor , diabetes mellitus
The renoprotective effect of vasopressin V2 receptor antagonist (V2RA) is currently being tested in a clinical trial in early autosomal dominant polycystic kidney disease (ADPKD). If efficacious, this warrants life-long treatment with V2RA, however, with associated side effects as polydipsia and polyuria. We questioned whether we could reduce the side effects without influencing the renoprotective effect by starting the treatment later in the disease or by lowering drug dosage.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom